IP6K3

IP6K3 is a cytoplasmic inositol hexakisphosphate kinase that converts IP6 to the inositol pyrophosphate InsP7, distinguishing it from the nuclear IP6K2 and the dual-localized IP6K1 (PMID:11502751). Beyond this catalytic role, IP6K3 acts as a cytoskeleton-associated organizer in two distinct cellular contexts: it is enriched in cerebellar Purkinje cells where it physically binds adducin and spectrin, and its loss perturbs the adducin–spectrin interaction, distorting Purkinje cell structure and synapse number and impairing motor learning and coordination (PMID:26245967); and it concentrates at the leading edge of migrating cells where it associates interdependently with dynein intermediate chain 2 (DIC2) to drive focal adhesion turnover, with loss causing motility defects, impaired dendritic growth, and brain malformations (PMID:30718399). In neurons it additionally governs synaptic vesicle dynamics, with knockout reducing the readily releasable vesicle pool and synaptic facilitation at hippocampal Schaffer collateral synapses (PMID:35936490). Systemically, genetic deletion of Ip6k3 in mice improves glucose tolerance and insulin sensitivity, reduces fat mass, and extends lifespan, alongside reduced cardiac S6 phosphorylation, establishing IP6K3 as a regulator of metabolic homeostasis and longevity (PMID:27577108). Transcription of IP6K3 is a direct glucocorticoid receptor target repressed by the cofactor PA1, which blocks GR binding to the IP6K3 promoter (PMID:23161582).

1. 2001 High

   Established that IP6K3 is a catalytically active third inositol hexakisphosphate kinase with a distinct subcellular distribution, defining it as a separate enzyme rather than a redundant copy of IP6K1/2.

   Evidence In vitro IP7 production assay, cellular fractionation, and sequence analysis

   PMID:11502751

   Open questions at the time

   • No structural model of the catalytic site
   • Physiological substrate flux and InsP7 targets in vivo not defined
   • Functional consequence of cytoplasmic localization unresolved at this stage
2. 2012 Medium

   Answered how IP6K3 expression is controlled, showing it is a direct glucocorticoid receptor transcriptional target whose induction is repressed by the cofactor PA1.

   Evidence ChIP and re-ChIP at the endogenous IP6K3 promoter with luciferase reporter assays

   PMID:23161582

   Open questions at the time

   • Physiological conditions driving GR-dependent IP6K3 induction unclear
   • Whether transcriptional regulation links to the metabolic phenotype untested
3. 2015 High

   Identified the first physical partners and tissue-specific function of IP6K3, linking it to cytoskeletal organization in cerebellar Purkinje cells and to motor behavior.

   Evidence Reciprocal Co-IP with adducin and spectrin plus knockout mouse cerebellar morphology, synapse counting, and motor behavior assays

   PMID:26245967

   Open questions at the time

   • Whether IP6K3 catalytic activity (InsP7) is required for the adducin–spectrin effect not separated from a scaffolding role
   • Molecular basis of adducin/spectrin binding undefined
4. 2016 Medium

   Demonstrated that IP6K3 deletion improves systemic metabolism and extends lifespan, positioning IP6K3 as a regulator of metabolic homeostasis and aging.

   Evidence Ip6k3 knockout mouse metabolic phenotyping with glucose/insulin tolerance tests, body composition, plasma metabolites, and cardiac S6 phosphorylation

   PMID:27577108

   Open questions at the time

   • No independent replication reported
   • Tissue responsible for the metabolic/longevity phenotype not pinpointed
   • Mechanistic link between InsP7 and S6 signaling not established
5. 2016 Low

   Linked a promoter SNP to IP6K3 expression level, providing a candidate basis for inter-individual variation in IP6K3 activity.

   Evidence Luciferase reporter assay comparing IP6K3 promoter SNP (rs28607030) variants

   PMID:27345265

   Open questions at the time

   • Single luciferase assay without endogenous validation
   • No demonstration of altered IP6K3 protein or phenotype in carriers
6. 2019 High

   Revealed a second cytoskeletal function for IP6K3 at the migrating cell leading edge through interdependent recruitment with DIC2 to drive focal adhesion turnover, connecting IP6K3 to motility and brain development.

   Evidence Immunofluorescence and TIRF microscopy, reciprocal Co-IP with DIC2, and knockout cell/mouse focal adhesion, motility, and dendritic growth assays

   PMID:30718399

   Open questions at the time

   • Whether InsP7 production is required for DIC2 cooperation untested
   • Relationship between the Purkinje adducin/spectrin role and the leading-edge DIC2 role unclear
7. 2022 Medium

   Showed that IP6K3 controls presynaptic vesicle dynamics, reducing the readily releasable pool and synaptic facilitation, with effects opposite to IP6K1 on exocytosis.

   Evidence Knockout mice with pHluorin live imaging (VGLUT1/VGLUT2), CA1 field electrophysiology, shRNA knockdown, and pharmacological inhibition

   PMID:35936490

   Open questions at the time

   • Molecular target of IP6K3/InsP7 at the synaptic vesicle cycle unidentified
   • Basis for opposing IP6K1 vs IP6K3 effects on exocytosis unexplained
8. 2026 Low

   Implicated IP6K3 in phosphate-induced vascular smooth muscle calcification, distinguishing it from IP6K1/2 by its lack of transcriptional induction under pro-calcific conditions.

   Evidence siRNA knockdown of IP6K3 in primary human aortic VSMCs with calcification assays

   PMID:41683831

   Open questions at the time

   • Single knockdown experiment without rescue or independent confirmation
   • Pathway placement of IP6K3 in VSMC calcification not defined

• It remains unresolved whether IP6K3's diverse roles—cytoskeletal scaffolding, focal adhesion turnover, synaptic vesicle control, and metabolic regulation—depend on its InsP7 kinase activity or on activity-independent protein scaffolding, and which downstream effectors of InsP7 mediate each phenotype.
• No catalytic-dead separation-of-function experiments reported across phenotypes
• InsP7-dependent downstream effectors not identified for any tissue context
• No structural data to connect catalysis with partner binding